Entera Bio

About

Funding history · 15 rounds · $441.6M total

Headcount over time

Q&A

What is Entera Bio's primary focus as a biopharmaceutical company?

Entera Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered large molecule therapeutics, including peptides and therapeutic proteins, utilizing its proprietary N-Tab® platform.

When did Entera Bio go public and on which exchange?

Entera Bio went public on NASDAQ in July 2018.

What was the amount raised in Entera Bio's PIPE funding round in March 2025?

In March 2025, Entera Bio raised $8,000,000 in a PIPE funding round.

What are the key product candidates in Entera Bio's pipeline?

Entera Bio's pipeline includes treatments for osteoporosis, hypoparathyroidism, obesity, and metabolic syndromes.

What was the outcome of Entera Bio's Phase 2 study of EB613 for osteoporosis, as presented in September 2025?

In September 2025, Entera Bio presented positive results from its Phase 2 study of EB613, an oral treatment for osteoporosis, demonstrating significant improvements in trabecular and cortical bone parameters after six months, comparable to existing injectable treatments.

What significant regulatory milestone did Entera Bio achieve in July 2025 regarding its EB613 treatment?

In July 2025, Entera Bio received FDA agreement to support the New Drug Application (NDA) marketing application for its oral peptide treatment, EB613, with a single Phase 3 study, confirming Bone Mineral Density (BMD) as the primary endpoint.

What is the nature of Entera Bio's collaboration with OPKO Health, Inc. as of September 2024?

In September 2024, Entera Bio and OPKO Health, Inc. announced positive topline pharmacokinetic/pharmacodynamic (PK/PD) results from their collaborative research on a long-acting oxyntomodulin (OXM) analog, aiming to develop the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders.

What was the outcome of Entera Bio's PIPE funding round in December 2023?

In December 2023, Entera Bio closed a private placement, raising approximately $6.6 million from existing and new investors, which extended the company's cash runway into 2025.

What was the total amount of funding Entera Bio has raised to date?

Entera Bio has raised a total of $111,400,000 USD.

What is the current employee count range for Entera Bio?

Entera Bio has 11-50 employees.

Team · 13

Spiros Jamas

Chief Executive Officer

Gregory Burshtein

Chief of Research and Development

Dana Yaacov Garbeli

Chief Financial Officer

Hillel Galitzer

Chief Operating Officer

Geno J. Germano

Chairman of the Board and Independent Director

Miranda Toledano

Chief Executive Officer and Director

Haya Taitel

Independent Director

Sean Ellis

Independent Director

Steven D. Rubin

Independent Director

Yonatan Malca

Independent Director

Michal Kushnir

Program Manager

Osnat Bar-Peled

Executive Director of Intellectual Property (IP)

Constantin Itin

Lead, Pre-clinical and Bioanalytical Activities

Sectors & technology

Highlights

Tags